Yahoo Finance Today’s Research Reports on Aurinia Pharmaceuticals, Helius Medical Technologies, Aptose Biosciences and ImmunoVaccine Inc.
NEW YORK, NY / ACCESSWIRE / November 14, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI has Initiated Coverage Today on:
Aurinia Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=AUP.TO
Helius Medical Technologies, Inc.
https://rdinvesting.com/news/?ticker=HSM.TO
Aptose Biosciences Inc.
https://rdinvesting.com/news/?ticker=APS.TO
ImmunoVaccine Inc.
https://rdinvesting.com/news/?ticker=IMV.TO
Aurinia Pharmaceuticals stock moved 2.19% lower Monday, to close the day at $7.15. The stock recorded a trading volume of 39,686 shares, which was below its three months average volume of 51,926 shares. In the last year, Aurinia Pharmaceuticals shares have traded in a range of 2.75 - 14.17. The share price has gained 160.00% from its 52-week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $7.77 is below its 200-day moving average of $8.23. Shares of Aurinia Pharmaceuticals have gained approximately 152.65 percent year-to-date.
Access RDI's Aurinia Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=AUP.TO
On Monday, shares in Helius Medical Technologies, Inc. recorded a trading volume of 320,400 shares, which was above the three months average volume of 192,101 shares. The stock ended the day 8.20% lower at 2.80. The share price has gained 63.74% from its 52-week low with a 52-week trading range of 1.71 - 5.09.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $4.05 is greater than its 200-day moving average of $2.73. Shares of Helius Medical Technologies have gained approximately 45.83 percent year-to-date.
Access RDI's Helius Medical Technologies, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=HSM.TO
Aptose Biosciences stock jumped 20.47% Monday, to close the day at $2.59. The stock recorded a trading volume of 207,703 shares, which was above its three months average volume of 39,701 shares. In the last year, Aptose Biosciences shares have traded in a range of 1.05 - 2.63. The share price has gained 146.67% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $1.87 is greater than its 200-day moving average of $1.74. Shares of Aptose Biosciences have gained approximately 43.09 percent year-to-date.
Access RDI's Aptose Biosciences Inc. Research Report at:
https://rdinvesting.com/news/?ticker=APS.TO
On Monday, shares in ImmunoVaccine Inc. recorded a trading volume of 75,692 shares, which was below the three months average volume of 127,358 shares. The stock ended the day 1.37% lower at 1.44. The share price has gained 118.18% from its 52-week low with a 52-week trading range of 0.66 - 1.70.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $1.31 is greater than its 200-day moving average of $1.27. Shares of ImmunoVaccine have fallen approximately 7.88 percent year-to-date.
Access RDI's ImmunoVaccine Inc. Research Report at:
https://rdinvesting.com/news/?ticker=IMV.TO
Our Actionable Research on Aurinia Pharmaceuticals Inc. (TSX:AUP.TO), Helius Medical Technologies, Inc. (TSX:HSM.TO), Aptose Biosciences Inc. (TSX:APS.TO) and ImmunoVaccine Inc. (TSX:IMV.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com